In addition, in this latter study, low levels of BAX mRNA were identified in samples from 3 CLL patients treated with venetoclax, and in CLL cells from another patient it was shown that BAX mutations were enriched during venetoclax treatment. Here, BAX is linked to B-cell chronic lymphocytic leukemia.